Nature Medicine

Economics, equity and avoidable mortality
https://www.nature.com/articles/s41591-024-03303-0

Nature Medicine, Published online: 22 October 2024; doi:10.1038/s41591-024-03303-0 (https://www.nature.com/articles/s41591-024-03303-0)Two new studies characterize the unequal global burden of avoidable mortality and the economic value of reducing it — providing evidence to support targeted investment in health and longevity.

The Cannabis and Health Research Initiative will help integrate medicinal cannabis in healthcare
https://www.nature.com/articles/s41591-024-03288-w

Nature Medicine, Published online: 22 October 2024; doi:10.1038/s41591-024-03288-w (https://www.nature.com/articles/s41591-024-03288-w)The Cannabis and Health Research Initiative will help integrate medicinal cannabis in healthcare

Safety principles for medical summarization using generative AI
https://www.nature.com/articles/s41591-024-03313-y

Nature Medicine, Published online: 22 October 2024; doi:10.1038/s41591-024-03313-y (https://www.nature.com/articles/s41591-024-03313-y)Google’s development of MedLM found that risk management processes were an essential tool to protect patient safety.

Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial
https://www.nature.com/articles/s41591-024-03305-y

Nature Medicine, Published online: 21 October 2024; doi:10.1038/s41591-024-03305-y (https://www.nature.com/articles/s41591-024-03305-y)A randomized, sham-controlled, superiority trial of a 10-week course of home-based transcranial direct current stimulation found greater improvements in depressive symptoms with active compared to sham stimulation in major depressive disorder.

An ethics assessment tool for artificial intelligence implementation in healthcare: CARE-AI
https://www.nature.com/articles/s41591-024-03310-1

Nature Medicine, Published online: 18 October 2024; doi:10.1038/s41591-024-03310-1 (https://www.nature.com/articles/s41591-024-03310-1)An ethics assessment tool for artificial intelligence implementation in healthcare: CARE-AI

How to prepare for the next inevitable Ebola outbreak: lessons from West Africa
https://www.nature.com/articles/s41591-024-03295-x

Nature Medicine, Published online: 17 October 2024; doi:10.1038/s41591-024-03295-x (https://www.nature.com/articles/s41591-024-03295-x)Many lessons have been learned 10 years after the Ebola virus disease outbreak in West Africa, but urgent work is now needed to prevent another outbreak.

Systems education can train the next generation of scientists and clinicians
https://www.nature.com/articles/s41591-024-03315-w

Nature Medicine, Published online: 17 October 2024; doi:10.1038/s41591-024-03315-w (https://www.nature.com/articles/s41591-024-03315-w)Systems education can train the next generation of scientists and clinicians

Health AI needs meaningful human involvement: lessons from war
https://www.nature.com/articles/s41591-024-03311-0

Nature Medicine, Published online: 16 October 2024; doi:10.1038/s41591-024-03311-0 (https://www.nature.com/articles/s41591-024-03311-0)Health AI needs meaningful human involvement: lessons from war

🚀 Reach Over 200,000 Medical Subscribers!

Promote your content to a large, targeted audience on our Telegram channels.

Contact Admin for promotions:
@Updates_in_Medicine_Admin

Cell therapy for neurological disorders
https://www.nature.com/articles/s41591-024-03281-3

Nature Medicine, Published online: 15 October 2024; doi:10.1038/s41591-024-03281-3 (https://www.nature.com/articles/s41591-024-03281-3)This Review summarizes the state of clinical research on cell replacement therapy for neurological conditions, and discusses the challenges facing the field, from immunosuppression and therapeutic delivery to cost issues.

How to make cardiology clinical trials more inclusive
https://www.nature.com/articles/s41591-024-03273-3

Nature Medicine, Published online: 14 October 2024; doi:10.1038/s41591-024-03273-3 (https://www.nature.com/articles/s41591-024-03273-3)Cardiology trials continue to under-represent certain population groups relative to disease distribution; this Perspective outlines strategies to foster representativeness and create a research enterprise that meets the needs of people living with cardiovascular disease.

A chatbot changes the minds of conspiracy theorists
https://www.nature.com/articles/d41591-024-00073-7

Nature Medicine, Published online: 14 October 2024; doi:10.1038/d41591-024-00073-7 (https://www.nature.com/articles/d41591-024-00073-7)A study of over 2,000 people shows that interacting with a large language model reduced belief in conspiracy theories — including some related to COVID-19 — by providing tailored, one-on-one interactions and compelling evidence.

🔴🔴 We are back on Instagram

Join for latest trending medical research, news and guidelines

https://www.instagram.com/updates_in_medicine

Putting children’s safety at the heart of violence research
https://www.nature.com/articles/s41591-024-03291-1

Nature Medicine, Published online: 11 October 2024; doi:10.1038/s41591-024-03291-1 (https://www.nature.com/articles/s41591-024-03291-1)Research and interventions where children may disclose violence require effective, resourced and context-specific safeguarding response plans.

Lassa vaccines to save lives, spare economies and assist in pandemic preparedness
https://www.nature.com/articles/s41591-024-03332-9

Nature Medicine, Published online: 11 October 2024; doi:10.1038/s41591-024-03332-9 (https://www.nature.com/articles/s41591-024-03332-9)Lassa fever is a cryptic viral disease that is spread predominantly from rodents to humans in West Africa. We estimated the health-economic burden associated with Lassa fever, highlighting the gains to population health and economies that could be afforded by Lassa vaccines, several of which are currently in development.

Computational brain models map diversity embedded in aging and dementia
https://www.nature.com/articles/s41591-024-03318-7

Nature Medicine, Published online: 10 October 2024; doi:10.1038/s41591-024-03318-7 (https://www.nature.com/articles/s41591-024-03318-7)This study explored how diverse factors including neurocognitive disorders, socioeconomic inequalities, pollution and gender disparities influence brain aging in underserved populations (groups with limited access to essential services such as healthcare and education). Using deep learning on EEG and fMRI data, we identified brain-age gaps as key markers of accelerated brain aging and their connections to macrosocial determinants of health.

AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
https://www.nature.com/articles/s41591-024-03304-z

Nature Medicine, Published online: 09 October 2024; doi:10.1038/s41591-024-03304-z (https://www.nature.com/articles/s41591-024-03304-z)The primary report of the EMBARK phase 3 trial, testing the AAV-based gene therapy delandistrogene moxeparvovec in Duchenne muscular dystrophy, did not meet its primary endpoint of improvement in NSAA mobility scores compared to placebo. Secondary endpoints show that the therapy was safe and associated with improvements in micro-dystrophin expression and in individual mobility scores.

People with cardiac pacemakers require multidisciplinary care
https://www.nature.com/articles/s41591-024-03296-w

Nature Medicine, Published online: 09 October 2024; doi:10.1038/s41591-024-03296-w (https://www.nature.com/articles/s41591-024-03296-w)Echocardiographic screening during routine pacemaker checkups identifies pacing-induced cardiomyopathy in more than one-third of patients, requiring multidisciplinary, guideline-directed follow-up care.

Lessons from a negative gene therapy trial for Duchenne muscular dystrophy
https://www.nature.com/articles/s41591-024-03316-9

Nature Medicine, Published online: 09 October 2024; doi:10.1038/s41591-024-03316-9 (https://www.nature.com/articles/s41591-024-03316-9)Delandistrogene moxeparvovec received FDA approval after a negative trial, which highlights the many complexities and challenges of drug development in this setting.